Global Glioblastoma Multiforme (GBM) Treatment Market Expected to Reach $3.66 Billion by 2028

Spread the love

Overview and Scope
Glioblastoma multiforme (GBM) treatment refers to the management and care of a patient suffering from glioblastoma multiforme, a kind of brain or spinal cord tumor that grows quickly. Adults with this primary malignant brain tumor have the highest prevalence rate.

Sizing and Forecast
The glioblastoma multiforme (gym) treatment market size has grown rapidly in recent years. It will grow from $2.23 billion in 2023 to $2.47 billion in 2024 at a compound annual growth rate (CAGR) of 10.6%. The growth in the historic period can be attributed to increased incidence and prevalence, advancements in diagnostic techniques, clinical trials and research funding, collaborations and partnerships, improved understanding of tumor biology.

The glioblastoma multiforme (gym) treatment market size is expected to see rapid growth in the next few years. It will grow to $3.66 billion in 2028 at a compound annual growth rate (CAGR) of 10.3%. The growth in the forecast period can be attributed to emergence of immunotherapies, precision medicine advancements, expanded knowledge of genetic markers, patient advocacy and awareness, government support for rare diseases. Major trends in the forecast period include exploration of combination therapies, integration of artificial intelligence in diagnosis and treatment planning, rise in adoption of immunotherapeutic approaches, advance medical tools and equipment.

Order your report now for swift delivery, visit the link:
https://www.thebusinessresearchcompany.com/report/glioblastoma-multiforme-gbm-treatment-global-market-report

The glioblastoma multiforme (GBM) treatment market covered in this report is segmented –

1) By Treatment: Surgery, Radiation Therapy, Chemotherapy, Targeted Therapy, Tumor Treating Field (TTF) Therapy, Immunotherapy
2) By Drug Class: Temozolomide, Bevacizumab, Lomustine, Carmustine Wafers, Other Drug Classes
3) By Route of Administration: Oral, Parenteral, Other Route Of Administrations
4) By End-Use: Hospitals, Clinics, Ambulatory Surgical Centers

North America was the largest region in the glioblastoma multiforme (GBM) treatment market share in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the glioblastoma multiforme (gbm) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Intrigued to explore the contents? Secure your hands-on a free sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=8803&type=smp

Major Driver Impacting Market Growth
The increasing prevalence of brain disorders is expected to propel the growth of the glioblastoma multiforme (GBM) treatment market going forward. Brain disorders refer to abnormal functioning of the brain as well as the nerves found throughout the human body and the spinal cord. The increasing prevalence of brain disorders such as glioblastoma multiforme (GBM) is due to various contributing factors such as the aging population, compromised immune systems, overdiagnosis, ionizing radiation, air pollution, and others which creates the need for the treatment of brain disorders to improve well-being. For instance, according to the report published by Globocan, a US-based international agency for providing global cancer statistics, approximately 308,102 cancer cases were detected for the brain and central nervous system, and 251,329 deaths in the year 2020 globally. Additionally, according to a report published by the American Cancer Society, a US-based voluntary health organization dedicated to eliminating cancer, in 2022, it is estimated around 25,050 malignant tumors of the brain or spinal cord cancer cases will be diagnosed in the US. Therefore, the increasing prevalence of brain disorders is driving the growth of the glioblastoma multiforme (GBM) treatment market.

Key Industry Players
Major companies operating in the glioblastoma multiforme (gbm) treatment market report are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, AstraZeneca PLC, Amgen Inc., Teva Pharmaceutical Industries Ltd., Carl Zeiss AG, Sun Pharmaceutical Industries Limited, Jazz Pharmaceuticals Inc., Sumitomo Dainippon Pharma Oncology Inc., Varian Medical Systems Inc., Amneal Pharmaceuticals Inc., Elekta AB, ANI Pharmaceuticals Inc., Accord Healthcare Limited, The Eckert & Ziegler Group, Arbor Pharmaceuticals LLC, Loxo Oncology Inc., Karyopharm Therapeutics Inc., Celon Laboratories Pvt. Ltd., EnGeneIC Ltd., Zydus Pharmaceuticals Inc., Genenta Science S.r.l., Cantex Pharmaceuticals Inc., Vascular Biogenics Ltd., Seelos Therapeutics Inc, Angiochem Inc., Diffusion Pharmaceuticals Inc.

The glioblastoma multiforme (gbm) treatment market report table of contents includes:

1. Executive Summary

2. Glioblastoma Multiforme (GBM) Treatment Market Characteristics

3. Glioblastoma Multiforme (GBM) Treatment Market Trends And Strategies

4. Glioblastoma Multiforme (GBM) Treatment Market – Macro Economic Scenario
……….

32. Global Glioblastoma Multiforme (GBM) Treatment Market Competitive Benchmarking

33. Global Glioblastoma Multiforme (GBM) Treatment Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Glioblastoma Multiforme (GBM) Treatment Market

35. Glioblastoma Multiforme (GBM) Treatment Market Future Outlook and Potential Analysis

36. Appendix

https://goodprnews.com/distribution-board-market-share/

https://goodprnews.com/duchenne-muscular-dystrophy-market-growth/